US Medical Devices Ishares ETF (IHI)

Zimmer Biomet has trailed the broader market over the past year, and it continues to face skeptical sentiment from analysts regarding its near- to medium-term growth outlook.

While Edwards Lifesciences has underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Medical device stocks have started 2026 looking weak. But there are signs of life if you know where to look.

GE HealthCare Technologies has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Edwards Lifesciences has notably outperformed the broader market over the past year, and analysts remain bullish on the stock’s prospects.

Medtronic has outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.

Insulet has outperformed the broader market over the past year, and analysts remain strongly bullish on the company’s trajectory.

ResMed has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Despite Stryker’s underperformance relative to the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Zimmer Biomet has significantly underperformed the broader market and other medical device stocks over the past year, yet analysts remain optimistic about the stock’s prospects.